RecruitingEarly Phase 1NCT05093335

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

30 participants

Start Date

Oct 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialized PET scan (called Pentixafor-PET) to image tumors in people with blood cancers or solid tumors. The scan targets a protein called CXCR4 that appears on the surface of many cancer cells, potentially helping doctors see where the cancer is more clearly than standard scans. **You may be eligible if...** - You are a patient at Memorial Sloan Kettering Cancer Center (MSKCC) - You have a blood cancer such as certain lymphomas, multiple myeloma, or a related condition, OR you have a solid tumor such as lung cancer, meningioma, or adrenal gland tumor - You are 18 or older - If you are a woman who could become pregnant, you have a recent negative pregnancy test **You may NOT be eligible if...** - You are breastfeeding - You have a history of kidney problems (eGFR < 30) - You refuse participation or decline consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[68Ga]-Pentixafor

An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.


Locations(1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05093335


Related Trials